Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dianhydrogalactitol
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : $19.6 million
Deal Type : Private Placement
DelMar Announces $19.6 Million Private Placement Priced at-the-Market
Details : Company intends to use the net proceeds from the offering for the previously announced registration study for VAL-083 in newly diagnosed and recurrent glioblastoma multiforme, the 15-patient REM-001 confirmatory lead-in study and for working capital.
Brand Name : VAL-083
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 18, 2020
Lead Product(s) : Dianhydrogalactitol
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : $19.6 million
Deal Type : Private Placement
Lead Product(s) : Dianhydrogalactitol
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Adgero Biopharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
DelMar to Acquire Adgero Biopharmaceuticals, Expands Late-Stage Oncology Pipeline
Details : This combination brings together DelMar's first-in-class, DNA-targeting chemotherapeutic with proven anti-cancer activities with Adgero's photodynamic therapy platform.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 10, 2020
Lead Product(s) : Dianhydrogalactitol
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Adgero Biopharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?
KEY PRODUCTS
Reset All
Minakem is manufacturing small molecules APIs including corticosteroids